Research interests: Developing novel therapeutic strategies for the treatment of neurological disorders using disruptors of protein-protein interactions
My research has been focused on developing novel therapeutic strategies for the treatment of neurological disorders using disruptors of protein-protein interactions.
My protein-targeting group at ICOS Corporation (Bothell, WA) focused on therapeutic targets where the basic science suggested that protein-protein interactions are critical, but traditional approaches seeking inhibitors of enzyme function or blockade of receptor function failed to identify practical therapeutics. I have continued this research at Indiana University, focusing on developing a novel set of small molecule protein-protein interaction disruptors that inhibit the signaling process downstream of the excitatory glutamate receptor subtype NMDAR.
